Abstract Although retreatment with alemtuzumab in relapsing B-cell chronic lymphocytic leukemia (CLL) may be beneficial, there has thus far been no thorough analysis available on this topic. Data were collected from 30 chemotherapy-pretreated patients with progressive CLL who had received alemtuzumab twice in consecutive, distinct therapy lines. The median dose of alemtuzumab retreatment was 402 mg (range, 43-1,090 mg). Retreatment with alemtuzumab induced an overall response rate of 47%. From the start of alemtuzumab retreatment, median progression-free survival (PFS) and overall survival (OS) were 6.3 and 20.0 months, respectively. Response rates, PFS and OS upon alemtuzumab retreatment were correlated with response to initial alemtuzumab treatment, the time interval between the initial course of alemtuzumab and start of retreatment, and the hemoglobin concentration prior to
Introduction
Chronic lymphocytic leukemia (CLL) can be treated with various therapies in a sequential manner. The selection of standard therapies depends on patient characteristics and disease features. For younger (<60) and physically fit patients, a combination of fludarabine, cyclophosphamid and rituximab (FCR regimen) has proven highly effective as first-and second-line treatment option [1, 2] , whereas for elderly and frail patients, chlorambucil is still a good choice [3] . For CLL patients with 17p deletion, alemtuzumabbased regimens are recommended as first-line therapy [4, 5] . In addition, treatment with alemtuzumab is an established option for salvage therapy, particularly for patients who have failed alkylating agents and fludarabine. Alemtuzumab (MabCampath®, Genzyme) is a humanized monoclonal antibody that targets the CD52 cell surface glycoprotein, which is abundantly expressed on normal and malignant B-and T-lymphocytes. The therapeutic benefit of alemtuzumab has been demonstrated in phase II studies with pretreated CLL patients [6] [7] [8] [9] [10] [11] , in a phase II study with chemo-naïve CLL patients [12] , and was confirmed in a phase III trial (CAM307) with chemo-naïve CLL patients [4] . Routine use of alemtuzumab in clinical practice is feasible and relatively safe, as shown by the retrospective reports on pretreated CLL patients from our Austrian-Czech CLL Alemtuzumab Registry [13] [14] [15] .
Currently, there is little data on how to treat CLL patients with disease progression after alemtuzumab treatment. In our previous Alemtuzumab Registry report, we noted that a remarkable number of patients with progressive disease having received a first course of alemtuzumab were fit enough to receive a second course of alemtuzumab. Intriguingly, longlasting responses were observed among patients retreated with alemtuzumab. To date, there are no clinical trials published on the efficacy and safety of alemtuzumab retreatment. Only single case reports [7, 16, 17] and series of six [18] and seven CLL patients [19] have been published indicating clinical benefits from alemtuzumab retreatment.
In this survey, we retrospectively investigated the efficacy and toxicity of alemtuzumab retreatment in 30 patients with CLL. All cases had received a second course of alemtuzumab as monotherapy due to progressive disease (PD) after a treatment-free interval following the first alemtuzumab treatment. Patients' characteristics and clinical features predicting clinical benefit of alemtuzumab retreatment were analyzed.
Patients and methods

Patients
This retrospective survey was conducted retrieving clinical data from a large data base of 196 pretreated patients with CLL who received alemtuzumab as monotherapy. The kind and sequence of prior therapy regimens is detailed in Table 2 . Thirty patients selected for this analysis had received a second course of alemtuzumab as the next therapy ("alemtuzumab retreatment"). The indication to re-induce alemtuzumab was considered by the treating physician; arguments for choosing alemtuzumab rechallenge might have been lasting response upon alemtuzumab, good tolerability, and massive pre-treatments with chemotherapy ( Table 2 ). The data set included patient characteristics (Table 1) , pretreatment modalities, cumulative doses of alemtuzumab, response, reported toxicities, and disease course. Data were collected from 16 clinical centers in Austria, one hospital in South Tyrol (Italy), and a center in Brno (Czech Republic). In this survey, alemtuzumab retreatment was initiated between May 15, 2002 and December 27, 2007 . Final follow-up data available for this analysis were obtained on May 25, 2010 . The median observation time for this patient cohort was 20.9 months. Approval of the survey was obtained from the Ethics Committee at the Medical University of Innsbruck.
Treatment
Usually, the alemtuzumab dose was escalated during the first week of therapy by intravenous (IV) administration of 3 mg on day 1, 10 mg on day 2, and 30 mg on day 3. Subsequent doses of 30 mg were administered ordinarily three times per week for a projected 12 weeks, either IV (n =5) or subcutaneously (n=22). In three cases, mode of application was not reported. Policies regarding dosages of alemtuzumab varied widely and were left to the discretion of clinicians from participating centers. Anti-infective prophylaxis, with valacyclovir and trimethoprim-sulfamethoxazole, was given in accordance with accepted guidelines [20] .
Response evaluation
Patients who received at least one dose of alemtuzumab for retreatment were considered evaluable for safety and efficacy. Response or disease progression was evaluated according to the National Cancer Institute Working Group criteria [21] immediately after the last alemtuzumab administration, 2 months after the last antibody administration, and subsequently, in case of a delayed response. For documentation of complete response (CR), partial response (PR), or stable disease (SD), the clinical benefit had to persist for at least 2 months. Progression-free survival (PFS) was defined as time from first dose of alemtuzumab retreatment to disease progression or death, whichever occurred first. Overall survival (OS) was measured from initiation of alemtuzumab retreatment.
Statistical considerations
Comparison of response rates between patient subgroups (based on cytogenetic categories and other baseline characteristics prior to alemtuzumab) was carried out using Pearson's chi-square test. Eventrelated data (PFS and OS) were estimated using the Kaplan-Meier method, and comparison of outcomes between categorical subgroups was made using the logrank test. Univariate analysis was performed to determine correlations between baseline characteristics and PFS or OS. The significance level was set at P<0.05, in two-sided tests.
Results
Patient characteristics
Out of 196 patients followed in our registry, who had been treated first line with chemotherapy and later with alemtuzumab in second or higher line, 30 patients (15%) received retreatment with single-agent alemtuzumab and were therefore included in this study. Importantly, between the two lines of alemtuzumab therapy, no other CLL treatment was administered. Patient demographics, baseline characteristics, and therapy modalities at the start of alemtuzumab retreatment are detailed in Table 1 . For all individual cases, the cumulative alemtuzumab doses, treatment responses, and time intervals between both alemtuzumab series are detailed in Table 2 . Briefly, 22 patients were male (73%), and the median age was 66 years (range 50-81 years). The majority of the cases (63%) was refractory towards fludarabine, and presented with stage Rai 4 (53%). The median number of previous treatment lines (including the initial alemtuzumab course) was 4 (range, 2-12). The median interval between the last dose of alemtuzumab course I and start of alemtuzumab course II was 10.9 months (range, 0.9-39.6 months). For the 30 patients, the median dose of alemtuzumab course I was 552 mg (range 123-1093 mg) and in course II, 402 mg (range, 43-1,090 mg). Various clinical parameters with potential impact on the results of alemtuzumab retreatment with respect to response, clinical benefit, PFS, and OS were tested for their predictive value ( Table 1) . Results of this data analysis are presented in Table 3 . CR complete response; PR partial remission; SD stable disease; PD progressive disease; NE response not evaluable; NK not known; A alemtuzumab; C cyclophosphamide; Clb chlorambucil; F fludarabine; Dex dexamethasone; Pred prednisone; R rituximab (in patient ZM according to [32] ); RCD rituximab, cyclophosphamide, dexamethasone [33] ; IMVP16+Dex ifosfamide, etoposide, methotrexate, and dexamethasone; PCR paclitaxel, cyclophosphamide, rituximab [34] ; HD-C high-dose cyclophosphamide (prior to stem cell harvest); FMD fludarabine, mitoxantrone, dexamthasone; FCM fludarabine, cyclophosphamid, mitoxantrone; Nav vinorelbine; 2CDA cladribine; HAM high-dose cytarabine, mitoxantrone; CFAR cyclophosphamide, fludarabine, alemtuzumab, rituximab; CEOP cyclophosphamide, etoposide, vincristine, prednisone; R-B rituximab, bendamustine; RT radiotherapy
Response upon alemtuzumab retreatment Individual responses upon alemtuzumab treatment I and II are summarized in Table 2 . Briefly, 14 patients (47%) achieved a PR by alemtuzumab retreatment. Six patients (20%) manifested SD and nine patients (30%) PD. One patient was not available for response since he died during alemtuzumab retreatment for unknown reasons. Notably, 11 out of 13 patients (85%) who responded to the first alemtuzumab course responded again to the second course. The remaining two patients showed long-lasting SD (with PR at the blood level but persistent splenomegaly). Of note, three out of 11 patients (27%) with SD upon alemtuzumab course I showed PR upon alemtuzumab course II. Six out of six patients (100%) who were retreated with alemtuzumab although having progressed during or shortly after the first alemtuzumab course again experienced PD (Table 2 ). Response to alemtuzumab retreatment was correlated with the following characteristics at start of retreatment: Rai stage, presence or absence of bulky lymphadenopathy, peripheral blood leukocyte count, hemoglobin level, response to the initial alemtuzumab course, and the time interval between the alemtuzumab courses (Table 3 ). In this case series, response to alemtuzumab retreatment was not dependent on gender, age, platelet count or ß 2 -microglobulin level, and most remarkably not on cytogenetic-risk category, number of prior therapies, and refractoriness toward fludarabine. Regarding cases categorized by cytogenetic risk (n=20), response to alemtuzumab Progression-free survival after alemtuzumab retreatment Disease progression of CLL was documented at the time when the first signs of PD were recognized. During the follow-up period of this survey, all patients with alemtuzumab retreatment progressed, with the exception of one who suffered from early death (see above). The median PFS after start of alemtuzumab retreatment was 6.3 months (range, 0.9 months to 26.9 months; Fig. 1 ). Short PFS was related to the following clinical characteristics at start of alemtuzumab retreatment (Table 3 ): higher age; presence of anemia (Fig. 2a) and bulky lymphadenopathy; lack of response upon initial alemtuzumab therapy, and a short time interval between the finish of the initial alemtuzumab therapy and start of alemtuzumab retreatment (Fig. 2b) . As expected, PFS was significantly associated with the cumulative alemtuzumab dose applied and the clinical response achieved (Table 3) . Next, we investigated whether PFS, after starting alemtuzumab course I and II, differed when calculated for the cohort of these 30 patients. The median PFS after alemtuzumab course I was 8.9 months and after course II still 6.3 months. (p=0.150; Fig. 1 ). In the subset of responders (n =13) to the initial alemtuzumab course (Table 2) , median PFS was 9.4 months after alemtuzumab course I and 11.9 months after course II (P=0.312). However, also non-responders to alemtuzumab course I (n=17) benefited with a median PFS of 7.5 months, although this patient group showed a PFS of only of 3.3 months upon alemtuzumab retreatment (P=0.002).
Overall survival after alemtuzumab retreatment Median OS after initiation of alemtuzumab retreatment was 20.0 months for the total cohort of 30 CLL patients. Poor OS was associated with following clinical parameters present at start of alemtuzumab retreatment: higher age, presence of bulky lymphadenopathy, presence of anemia, lack of response upon initial alemtuzumab therapy; and short time interval between the alemtuzumab courses (Table 3) . On the contrary, an improved OS was seen in responders to alemtuzumab retreatment.
Disease progression
Patients with disease progression during or shortly after alemtuzumab therapy presented primarily with increasing peripheral blood lymphocyte counts (n=16; 53%), progressive lymphadenopathy (n=7; 23%), increasing splenomegaly 2 Kaplan-Meier plots illustrating progression-free survival (PFS) in 30 patients with chemotherapy pretreated CLL who received alemtuzumab retreatment. a According to absence or presence of anemia prior to alemtuzumab retreatment, PFS was 9.5 months and 3.1 months in patients with hemoglobin ≥11 g/dL or less, respectively (P<0.001). b Plotted according to the length of the treatment-free interval between end of initial alemtuzumab therapy and alemtuzumab retreatment, the median PFS was 9.9 and 4.1 months in patients with an interval ≥10.9 months or shorter, respectively (P=0.011) (n=2; 7%), and other clinical or laboratory features (rising LDH, cachexia, or other non-specified signs; n=5; 17%). 21%] ). Thrombocytopenia and neutropenia of grade IV were observed in four (17%) and three cases (13%), respectively. Of note, severe thrombocytopenia and neutropenia was comparably low also during first course of alemtuzumab in these 24 patients (thrombocytopenia grade IV, n=3 [13%]; neutropenia grade IV, n=2 [8%]). One patient died shortly after start of alemtuzumab retreatment, and the cause remains unknown.
CLL treatment following alemtuzumab retreatment
Twenty-two of the 30 cases received one or more further systemic therapies due to progressive disease after alemtuzumab retreatment ( Table 2 ). The following therapies were chosen: a third course of alemtuzumab in eight patients, of whom six had a PR to the second alemtuzumab therapy; rituximab-containing chemo-immuno therapy (n=8); rituximab monotherapy (n=2); chemotherapy (n=3); and dexamethasone plus rituximab (n=1). In the eight patients receiving a third alemtuzumab therapy, a PR was achieved in one and SD in two cases. Alemtuzumab administration was cessated in one case due to septicemia (Table 2) . One patient received combination therapy with cyclophosphamide, fludarabine, alemtuzumab, and rituximab and achieved an ongoing CR.
Discussion
In our previous retrospective reports [13] [14] [15] , we demonstrated that routine use of alemtuzumab in CLL patients was beneficial and safe, in line with prospective clinical studies [6] [7] [8] [9] [10] [11] [12] . Interestingly, it became evident that a considerable portion of patients received alemtuzumab retratment subsequently. A prospective clinical study addressing the role of alemtuzumab retreatment in CLL is unlikely to be performed in the foreseeable future. Thus, we aimed at investigating the utility of alemtuzumab retreatment in retrospect and at identifying factors that can be used for adequate patient selection.
Who were the patients subjected to alemtuzumab rechallenge? Most likely those in whom a benefit could be expected, e.g., due to response upon prior alemtuzumab, or because other therapy options were not available, e.g., due to massive pretreatment (Table 2 ). For the physicians using alemtuzumab retreatment, another pro-argument might have been good tolerability during first course of alemtuzumab; indeed, in our series, the rate of grade IV hematoxicity was definitely low in both first and second course of alemtuzumab, when compared to the literature [6, 9, 10] and to the whole series of our CLL/alemtuzumab registry (with grade IV neutropenia and thrombocytopenia of 33% and 19%, respectively [14] ). Similarly, Hui et al. [18] observed low hematological toxicity in the six patients who received a second course of alemtuzumab.
Thus far, the topic of alemtuzumab retreatment has not been systematically investigated. Egyed et al. presented a patient with CLL with 11q deletion who meanwhile had received five courses of alemtuzumab within a 5-year interval and had responded well to each course [17] . Thieblement et al. presented a case series from a total of 17 patients with CLL relapsing after alemtuzumab, seven of whom received alemtuzumab retreatment. The median interval between the two alemtuzumab courses was 10 months. Within the first month of retreatment, normalization of blood lymphocytosis was observed in all cases, and four patients had a response of lymphadenopathies and splenomegaly subsequently. Median time to progression was 5.8 months [19] . Hui et al. [18] documented six patients who received alemtuzumab retreatement. Among those, two achieved PR and three SD.
For T-PLL, alemtuzumab is considered a standard therapy option for first and following therapy lines. In T-PLL, alemtuzumab retreatment dosing and response have been studied retrospectively [22] . The authors found that 13 of 39 patients with T-PLL treated initially with alemtuzumab received alemtuzumab retreatment, and the median dose of retreatment was 263 mg (range, 40-1,325 mg). Notably, six patients responded (46%) to the second alemtuzumab course; and response to retreatment was seen only in patients who had achieved a complete response upon first alemtuzumab treatment.
In our study, a quite favorable response rate of 47% upon alemtuzumab retreatment was observed. Most important, it was possible to identify factors predicting responsiveness to alemtuzumab retreatment (Table 3) . Clinically relevant is the finding that presence of anemia at start of alemtuzumab retreatment is clearly indicating inferior outcome, corresponding to our observation that anemia is an independent risk factor of inferior outcome at first course of alemtuzumab treatment [13, 15] . Obviously, factors predictive of response to alemtuzumab retreatment correspond closely with favorable PFS and OS after start of alemtuzumab retreatment (Table 3 ). This data compares well with results achieved with retreatment of CLL using purine analogs [23, 24] ; of indolent lymphoma using rituximab [25] ; of myeloma using bortezomib [26, 27] , and of solid tumors such as ovarian [28] and lung cancer [29] using platinum-based chemotherapy. There is strong evidence from retreatments with various agents in different malignancies that the response upon initial treatment and the interval between initial treatment and retreatment were predictive for both clinical benefit and disease outcome [23] [24] [25] [26] [27] [28] [29] .
In conclusion, our results from this retrospective survey corroborate and expand preliminary data indicating that for carefully selected cases with relapsing or progressive CLL, alemtuzumab retreatment provides a valid therapeutic option. Notably, recent guidelines on the routine use of alemtuzumab in CLL established by an international panel of experts underscore the option of alemtuzumab retreatment [20] , based on recently presented, preliminary data from our study [30] .
